Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025

Dr. Anastasia Constantinidou, a respected Pathologist-Oncologist and Assistant Professor, has been nominated for the Madame Figaro Woman of the Year 2025 in the Scientist / Academician category. This nomination is a recognition of her impactful work in clinical oncology, medical education, and research at both national and international levels.

A Distinguished Career in Oncology

Dr. Anastasia Constantinidou serves as a Pathologist-Oncologist at the Bank of Cyprus Oncology Center and as an Assistant Professor of Pathology–Hematology at the University of Cyprus Medical School. Her medical training and specialization in pathological oncology were completed at world-renowned institutions including the Royal Marsden Hospital, the Institute of Cancer Research, and the University of London.

Since completing her PhD in London in 2015, Dr. Konstantinidou has devoted her career to advancing cancer care in Cyprus and beyond. Her work bridges patient-centered clinical practice with cutting-edge oncology research and education. She is the local principal investigator in several European and international projects, including CARDIOCARE (HORIZON 2020), ECHOs (HORIZON Europe), ECAN and ECAN PLUS (EU4Health), and BIOBREAST (RIF Cyprus). These projects address precision oncology, rare cancers, and the integration of cardiovascular safety in breast cancer care.

Contributions to Research and Innovation

Her contributions have been recognized by prestigious awards such as the Cyprus Research and Innovation Foundation’s “Young Researcher Award” (Life Sciences) in 2020, reflecting her dedication to scientific progress in oncology.

She plays a vital role in international and national research programs and regularly represents Cyprus at major global scientific congresses. Notably, she was Chair and Speaker at the 2024 ESMO Sarcoma & Rare Cancers Annual Meeting in Lugano, leading discussions on real-world data in soft tissue cancers. She has authored over 40 peer-reviewed publications in leading journals such as Lancet Oncology, Clinical Cancer Research, Nature Reviews Clinical Oncology, and Annals of Oncology.

Research Interests

• Translational oncology and gene expression as therapeutic targets

• Early-phase clinical trials of novel agents

• Epigenetic mechanisms in cancer progression

• Functional imaging in disease monitoring and response assessment

Commitment to Medical Education

Dr. Constantinidou is also known for her commitment to education. In 2023, she coordinated and served as keynote speaker at the 1st Oncology Forum of the Bank of Cyprus Oncology Center, engaging medical, nursing, and pharmacy students in dialogue on pathological oncology. She is also a dedicated faculty member in the University of Cyprus Medical School’s first graduate program. Through her academic role, she fosters the next generation of healthcare professionals, while promoting a culture of excellence and innovation.

A passionate advocate for science and education, Dr. Constantinidou has inspired many through her commitment to academic excellence and public engagement. Her work reflects a blend of scientific rigor, intellectual leadership, and an unwavering belief in the power of knowledge to drive societal progress.

She is the coordinator and academic lead of the MSc program in Precision Medicine in Clinical Practice, the first postgraduate degree of the University of Cyprus Medical School, which welcomed its first cohort in 2021.

Announcing her nomination via a heartfelt message to her classmates and supporters, she wrote:

“Good afternoon to my classmates! I’m on a campaign trail… for the Madame Figaro Scientist / Academician award until July 25. Thank you so much to all who have heard about this and have already voted! For those who want to vote I leave the details here. The easiest way is with sms. Thank you very much!”

A Voice for Science and Progress

Dr. Anastasia Constantinidou’s nomination for the Madame Figaro Awards is not only a personal honor, it is a celebration of scientific dedication, compassion in care, and leadership in a field that continues to transform lives.

“Every step I take has been dedicated to cancer research and my patients. I am proud to represent Cyprus in the field of Oncology and thrilled to be nominated for Madame Figaro Women of the Year 2025,” she shared.

Top Publications

Dr. Anastasia Constantinidou has published extensively in high-impact peer-reviewed journals across oncology, translational research, and cancer therapeutics. Selected publications include:

• Constantinidou A, Jones RL. Maintenance treatment in sarcomas: who is it for? Ann Oncol. 2025 May 13:S0923-7534(25)00194-2.

• Panagi M, Mpekris F, Voutouri C, et al. Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition. Clin Cancer Res. 2024 Jun 3;30(11):2582-2597.

• Alexandraki A, Papageorgiou E, Zacharia M, et al. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. Cancers (Basel). 2023 Jun 22;15(13):3290.

• Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics. 2022 Aug 15;12(14):6106-6129.

• Constantinidou A, Marcou Y, Toss MS, et al. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin Cancer Res. 2022 Oct 14;28(20):4435-4443.

• Mpekris F, Panagi M, Voutouri C, et al. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Adv Sci (Weinh). 2020 Dec 13;8(3):2001917.

• Guo C, Chénard-Poirier M, Roda D, et al. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma. Lancet Oncol. 2020 Nov;21(11):1478-1488.

• Constantinidou A, Sauve N, Stacchiotti S, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 Aug;5(4):e000787.

• Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020 Mar;39(10):2040-2054.

• Constantinidou A, Alifieris C, Trafalis DT. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A prosperous new era in cancer active immunotherapy. Pharmacol Ther. 2019 Feb;194:84-106.

Support Her Candidacy

Voting is open until July 25, 2025, and can be done through the following methods:

• Online: https://awards.madamefigaro.cy
• By Phone: Call 900 31 056 (Category: Scientist / Academician), vote number 1
• By SMS: Text MF61 [space] Your Full Name to 5588

Read more about oncology news and global cancer leadership at OncoDaily.